Olema Pharmaceuticals (OLMA) Profit After Tax (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Profit After Tax data on file, last reported at -$53.1 million in Q1 2026.

• Profit After Tax for Q1 2026 came in at -$53.1 million, down 74.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$185.2 million (down 43.65% YoY), and the FY2025 annual result was -$162.5 million, down 25.47% from the prior year.
• Profit After Tax retreated to -$53.1 million in Q1 2026 per OLMA's latest filing, from -$46.1 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$20.1 million in Q2 2023 and troughed at -$53.1 million in Q1 2026.
• A 5-year average of -$32.1 million and a median of -$30.4 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax plunged 100.28% in 2022, then jumped 38.84% in 2023.
• A 5-year view of Profit After Tax shows it stood at -$26.2 million in 2022, then dropped by 2.27% to -$26.8 million in 2023, then dropped by 25.38% to -$33.6 million in 2024, then plunged by 37.22% to -$46.1 million in 2025, then decreased by 15.26% to -$53.1 million in 2026.
• Business Quant data shows OLMA's Profit After Tax at -$53.1 million in Q1 2026, -$46.1 million in Q4 2025, and -$42.2 million in Q3 2025.